AbbVie Inc - Company Profile
Powered by 
All the data and insights you need on AbbVie Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AbbVie Inc Strategy Report
- Understand AbbVie Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreAbbVie Inc (AbbVie) is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn's disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn's disease, Parkinson's disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
Headquarters
United States of America
Address
1 N Waukegan Rd, North Chicago, Illinois, 60064
Website
www.abbvie.com
Telephone
1 847 9327900
No of Employees
50,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABBV (NYSE)
Revenue (2022)
$54.3B
-6.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-58.9%
(2022 vs 2021)
Market Cap*
$287.3B
Net Profit Margin (2022)
XYZ
-56.1%
(2022 vs 2021)
* As of and is in US$
AbbVie Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Humira |
| Products for treating Autoimmune Diseases: | Rinvoq |
| Rheumatoid Arthritis | Skyrizi |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company secured approval from the US Food and Drug Administration for its monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) to treat patients with certain types of ovarian cancer. |
| 2024 | Contracts/Agreements | In March, the company entered into an agreement to acquire Landos, a biopharmaceutical company. |
| 2024 | Regulatory Approval | In March, Allergan Aesthetics secured U.S. FDA approval for JUVEDERM VOLUMA XC for injection in the temple region. |
Competitor Comparison
| Key Parameters | AbbVie Inc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | North Chicago | New Brunswick | Basel | Kenilworth | New York |
| State/Province | Illinois | New Jersey | - | New Jersey | New York |
| No. of Employees | 50,000 | 131,900 | 103,605 | 72,000 | 88,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard A. Gonzalez | Chief Executive Officer; Chairman | Executive Board | 2013 | 70 |
| Scott T. Reents | Chief Financial Officer; Executive Vice President | Senior Management | 2022 | 56 |
| Robert A. Michael | President; Chief Operating Officer | Senior Management | 2023 | 53 |
| Thomas J. Hudson, M.D. | Chief Scientific Officer; Senior Vice President - Research & Development | Senior Management | 2022 | 62 |
| Jeffrey R. Stewart | Chief Commercial Officer; Executive Vice President | Senior Management | 2020 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward